Latin America is set to gain more and more momentum as a possible destination for clinical trials
"One of the first major aspects of the region is that it has a growing population and a population which at the same time exhibits many of the major diseases seen in other global regions," explained Dr Kermani. "There have been notable increases in several Latin American countries of chronic diseases, particularly viral, cardiovascular, respiratory and metabolic conditions, and yet a persistence of diseases associated with poverty and social inequality."
Ironically, despite the persistence of these diseases, it is the ever improving economic situations in countries such as Brazil, Mexico and Argentina that gives the region the more solid footing which will inevitably make the process of selecting it as a clinical trial destination easier for the key manufacturers.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.